Brief: Meiragtx Announces Positive Top-Line Data From The Mgt009 Phase 1/2 Clinical Study Demonstrating Safety And Improvement In Multiple Domains Of Vision In X-Linked Retinitis Pigmentosa Patients Treated With Botaretigene Sparoparvovec (Aav-Rpgr) Compared To Untreated Randomized Control

MeiraGTx Holdings

28/06/2022 12:29

June 28 (Reuters) - MeiraGTx Holdings PLC  MGTX.O :
    * MEIRAGTX ANNOUNCES POSITIVE TOP-LINE DATA FROM THE MGT009
PHASE
1/2 CLINICAL STUDY DEMONSTRATING SAFETY AND IMPROVEMENT IN
MULTIPLE DOMAINS OF VISION IN X-LINKED RETINITIS PIGMENTOSA
PATIENTS TREATED WITH BOTARETIGENE SPAROPARVOVEC (AAV-RPGR)
COMPARED TO UNTREATED RANDOMIZED CONTROL
    * MEIRAGTX HOLDINGS PLC - BOTARETIGENE SPAROPARVOVEC
TREATMENT WAS
FOUND TO BE GENERALLY SAFE AND WELL-TOLERATED
    * MEIRAGTX HOLDINGS PLC - SIGNIFICANT IMPROVEMENTS WERE
DEMONSTRATED IN MULTIPLE DIFFERENT ENDPOINTS IN BOTARETIGENE
SPAROPARVOVEC-TREATED PATIENTS

Source text for Eikon:  ID:nGNX99NtyP 
Further company coverage:  MGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))